A Phase 1b/2 Clinical Study Evaluating the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in Subjects With Lupus Nephritis
Latest Information Update: 07 Jul 2025
At a glance
- Drugs MIL-62 (Primary)
- Indications Lupus nephritis; Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Beijing Mabworks Biotech
Most Recent Events
- 07 Jul 2025 New trial record